[不稳定的心力衰竭:避免经常住院的实用指南]
Deutsche medizinische Wochenschrift (1946)
|February 5, 2025
概括
早期识别和治疗恶化的心力衰竭是减少住院治疗的关键. 本指南建议基于指导方针的治疗,Vericiguat,以及密切的随访,以改善心力衰竭患者的结果.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 心力衰竭是德国住院的主要原因之一.
- 改善的预防策略包括基于指导方针的治疗,药物升级和远程医疗.
- 早期识别恶化的心力衰竭对于有效的管理至关重要.
研究的目的:
- 为恶化的心力衰竭提供综合和协调治疗的建议.
- 概述稳定心力衰竭,减少死亡率和减少住院治疗的策略.
- 为了解决针对恶化的心力衰竭管理缺乏专门的指导方针.
主要方法:
- 使用临床检查,生物化学标记物 (尿素) 和高级成像 (心声,肺部超声波,CT,MRI).
- 整合创新的心脏远程监测,用于早期检测.
- 应用指导方针推的医疗治疗和启动Vericiguat治疗心力衰竭与减少喷射分数.
主要成果:
- 早期发现恶化的心力衰竭可以及时进行干预.
- 建议在住院期间和出院后6周内开始和增加治疗量.
- 综合管理旨在改善患者的治疗结果,并减少医疗保健利用率.
结论:
- 治疗恶化的心力衰竭的协调方法是必不可少的.
- 推Vericiguat用于心力衰竭的特定患者群体,心脏衰竭的射出分数减少.
- 有效的管理策略可以显著改善患者的预后,并减少住院治疗.
相关概念视频
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
Pulse rhythm
754
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
754
Increased pulse rate
636
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
636


